Holen Sie sich die Stockscreener-App
11.25
0.79%
-0.09
Handel nachbörslich:
11.25
Schlusskurs vom Vortag:
$11.34
Offen:
$11.36
24-Stunden-Volumen:
584.19K
Relative Volume:
0.51
Marktkapitalisierung:
$886.49M
Einnahmen:
$175.11M
Nettoeinkommen (Verlust:
$-221.25M
KGV:
-3.6867
EPS:
-3.0515
Netto-Cashflow:
$-167.00M
1W Leistung:
+6.84%
1M Leistung:
+5.44%
6M Leistung:
-3.10%
1J Leistung:
+130.53%
1-Tages-Spanne:
$11.03
$11.42
1-Wochen-Bereich:
$10.75
$11.83
52-Wochen-Spanne:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
11.25 | 893.58M | 175.11M | -221.25M | -167.00M | -3.0515 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-12-12 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Quarterly Recap: How correlated is Phathom Pharmaceuticals Inc to the S P5002026 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Portfolio Recap: Is Phathom Pharmaceuticals Inc a cyclical or defensive stockQuarterly Profit Report & Weekly Stock Breakout Alerts - baoquankhu1.vn
PHAT Technical Analysis & Stock Price Forecast - Intellectia AI
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - stocktitan.net
Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily
Portfolio Recap: What are the risks of holding Phathom Pharmaceuticals IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn
Phathom Pharmaceuticals Inc (PHAT) Stock News & Articles - 247wallst.com
Phathom upgraded at Barclays following pullback, Voquezna optimism - MSN
Barclays upgrades Phathom Pharmaceuticals (PHAT) - MSN
Phathom upgraded at Barclays following pullback, Voquezna optimism ) - Seeking Alpha
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Analyst Upgrade - MarketBeat
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday - Benzinga
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays - MarketBeat
Barclays Upgrades Phathom Pharmaceuticals to Overweight From Equal Weight, Adjusts PT to $18 From $16 - MarketScreener
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook - investing.com
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook By Investing.com - Investing.com Canada
Weekly Recap: Does Phathom Pharmaceuticals Inc offer margin of safetyTrade Performance Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Whats Phathom Pharmaceuticals Incs historical return2026 Market WrapUp & Weekly High Return Forecasts - baoquankhu1.vn
Analyst Calls: Does Phathom Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Safe Entry Momentum Tips - baoquankhu1.vn
Millennium (PHAT) group discloses 4.18M shares (5.3%) in Phathom (PHAT) - stocktitan.net
Phathom Pharmaceuticals (PHAT) director gifts 80,000 shares to trust - Stock Titan
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - The Globe and Mail
Phathom Pharmaceuticals (PHAT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Precision Trading with Phathom Pharmaceuticals Inc. (PHAT) Risk Zones - Stock Traders Daily
Certain Performance Stock Units of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth - MSN
GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Tech Rally: Does Phathom Pharmaceuticals Inc have strong fundamentalsQuarterly Trade Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
PHAT Should I Buy - Intellectia AI
Propel Bio Management LLC Sells 370,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up - TipRanks
PHAT Technical Analysis & ETF Price Forecast - Intellectia AI
Phathom Pharmaceuticals Hits Day Low of $12.32 Amid Price Pressure - Markets Mojo
Phathom (PHAT) accounting chief gets RSUs, surrenders shares for tax - Stock Titan
PHAT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Phathom (PHAT) Q4 2025 Earnings Call Transcript - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.5%Should You Sell? - MarketBeat
Helicobacter pylori Infection Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | RedHill Biopharma, Phathom Pharma, Takeda Pharma, Otsuka Pharma, Juvisé Pharma, AbbVie, TenNor - Barchart.com
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why - Insider Monkey
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why - Bitget
Phathom Pharmaceuticals (PHAT) Is Up 10.0% After Guiding to 2026 Operating Profitability and Raising Capital - simplywall.st
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating - TipRanks
Phathom Pharmaceuticals (NASDAQ:PHAT) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses - Yahoo Finance
Guggenheim Raises Price Target for Phathom Pharmaceuticals (PHAT) to $25 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):